How long do revised and multiply revised knee replacements last? An analysis of the National Joint Registry [0.03%]
翻修膝关节置换术的假体生存率分析：基于国家关节登记处数据的研究
Kevin Deere,Michael R Whitehouse,Setor K Kunutsor et al.
Kevin Deere et al.
Background: Knee replacements are common and effective operations but patients that undergo this intervention are at risk of needing subsequent costly and often complex revision surgery with poorer outcomes than primary s...
Nick D Clement
Nick D Clement
The Lancet Rheumatology
The Lancet Rheumatology
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study [0.03%]
利妥昔单抗治疗风湿性关节炎患者接种两剂和三剂SARS-CoV-2疫苗后的体液及细胞免疫反应：前瞻性队列研究
Ingrid Jyssum,Hassen Kared,Trung T Tran et al.
Ingrid Jyssum et al.
Background: In rituximab-treated patients with rheumatoid arthritis, humoral and cellular immune responses after two or three doses of SARS-CoV-2 vaccines are not well characterised. We aimed to address this knowledge gap...
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial [0.03%]
早期广泛性系统性硬化症中阿巴西普安全性和有效性的研究（ASSET）：二期双盲随机试验的开放标签延长试验
Lorinda Chung,Cathie Spino,Richard McLain et al.
Lorinda Chung et al.
Background: Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis in a phase 2, double-blind randomised trial, with potential efficacy at 12 months. We report here the results of an open...
Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab [0.03%]
阿达木单抗或苏金单抗治疗轴向脊柱关节炎患者接种信使RNA新冠疫苗后的体液及细胞免疫反应
Jitka Smetanova,Zuzana Strizova,Anna Sediva et al.
Jitka Smetanova et al.
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries [0.03%]
阿拉伯19个国家中慢性风湿病患者和医疗专业人员对COVID-19疫苗可接受性的横断面研究
Lina El Kibbi,Mona Metawee,Ihsane Hmamouchi et al.
Lina El Kibbi et al.
Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination [0.03%]
风湿病患者在接种COVID-19疫苗时的免疫调节和免疫抑制药物调整情况
Medha Barbhaiya,Jonah M Levine,Vivian P Bykerk et al.
Medha Barbhaiya et al.
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study [0.03%]
巴西系统性红斑狼疮和类风湿关节炎患者COVID-19灭活疫苗二期临床试验亚组分析：血清学阳性和阴性患者的免疫原性和安全性研究
Nadia E Aikawa,Leonard V K Kupa,Sandra G Pasoto et al.
Nadia E Aikawa et al.
Background: We aimed to examine the immunogenicity pattern induced by the inactivated SARS-CoV-2 vaccine CoronaVac (Sinovac Life Sciences, Beijing, China) in SARS-CoV-2 seropositive patients with autoimmune rheumatic dise...